Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $8.00.

A number of research firms have recently commented on PSTV. D Boral Capital upgraded Plus Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 3rd. HC Wainwright lowered their price objective on Plus Therapeutics from $5.50 to $3.00 and set a "buy" rating for the company in a research report on Friday, June 27th. Ascendiant Capital Markets upped their target price on shares of Plus Therapeutics from $20.50 to $21.00 and gave the stock a "buy" rating in a research report on Monday. D. Boral Capital reiterated a "buy" rating and issued a $5.00 price target on shares of Plus Therapeutics in a research note on Thursday, September 25th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Plus Therapeutics in a research note on Saturday, September 27th.

Plus Therapeutics Trading Up 21.6%

NASDAQ:PSTV opened at $0.89 on Tuesday. The company has a 50-day moving average price of $0.55 and a 200-day moving average price of $0.55. The stock has a market cap of $88.30 million, a price-to-earnings ratio of -0.40 and a beta of 0.81. Plus Therapeutics has a 12 month low of $0.16 and a 12 month high of $2.31.

Plus Therapeutics (NASDAQ:PSTV - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.08. The company had revenue of $1.39 million during the quarter, compared to the consensus estimate of $1.08 million. Equities analysts forecast that Plus Therapeutics will post -2.3 EPS for the current fiscal year.

Insider Buying and Selling at Plus Therapeutics

In related news, Director Robert P. Lenk purchased 110,000 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were bought at an average price of $0.49 per share, for a total transaction of $53,900.00. Following the purchase, the director directly owned 139,327 shares of the company's stock, valued at approximately $68,270.23. This represents a 375.08% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.79% of the stock is owned by insiders.

Institutional Investors Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. Jane Street Group LLC purchased a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 117,454 shares of the company's stock, valued at approximately $41,000. Jane Street Group LLC owned approximately 0.19% of Plus Therapeutics at the end of the most recent reporting period. 3.28% of the stock is currently owned by institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.